Sutro Biopharma, Inc. S09.F Stock
Sutro Biopharma, Inc. Price Chart
Sutro Biopharma, Inc. S09.F Financial and Trading Overview
Sutro Biopharma, Inc. stock price | 3.76 EUR |
Previous Close | 4.86 EUR |
Open | 4.86 EUR |
Bid | 4.86 EUR x 0 |
Ask | 5 EUR x 0 |
Day's Range | 4.86 - 4.86 EUR |
52 Week Range | 3.2 - 7.9 EUR |
Volume | 25 EUR |
Avg. Volume | 0 EUR |
Market Cap | 293.63M EUR |
Beta (5Y Monthly) | 0.882781 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.73 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.71 EUR |
S09.F Valuation Measures
Enterprise Value | 75.18M EUR |
Trailing P/E | N/A |
Forward P/E | -1.793358 |
PEG Ratio (5 yr expected) | 0.5 |
Price/Sales (ttm) | 3.9387 |
Price/Book (mrq) | 1.5768981 |
Enterprise Value/Revenue | 1.008 |
Enterprise Value/EBITDA | -0.596 |
Trading Information
Sutro Biopharma, Inc. Stock Price History
Beta (5Y Monthly) | 0.882781 |
52-Week Change | 57.81% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.9 EUR |
52 Week Low | 3.2 EUR |
50-Day Moving Average | 4.46 EUR |
200-Day Moving Average | 5.8 EUR |
S09.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 60.42M |
Float | 46.25M |
Short Ratio | N/A |
% Held by Insiders | 5.52% |
% Held by Institutions | 87.46% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -174.57% |
Operating Margin (ttm) | -177.12% |
Gross Margin | -96.62% |
EBITDA Margin | -169.11% |
Management Effectiveness
Return on Assets (ttm) | -24.94% |
Return on Equity (ttm) | -64.14% |
Income Statement
Revenue (ttm) | 74.55M EUR |
Revenue Per Share (ttm) | 1.39 EUR |
Quarterly Revenue Growth (yoy) | 114.90% |
Gross Profit (ttm) | N/A |
EBITDA | -126070000 EUR |
Net Income Avi to Common (ttm) | -130144000 EUR |
Diluted EPS (ttm) | -2.36 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 276.49M EUR |
Total Cash Per Share (mrq) | 4.58 EUR |
Total Debt (mrq) | 46.56M EUR |
Total Debt/Equity (mrq) | 25.11 EUR |
Current Ratio (mrq) | 5.112 |
Book Value Per Share (mrq) | 3.082 |
Cash Flow Statement
Operating Cash Flow (ttm) | -22187000 EUR |
Levered Free Cash Flow (ttm) | -52296500 EUR |
Profile of Sutro Biopharma, Inc.
Country | Germany |
State | CA |
City | South San Francisco |
Address | 111 Oyster Point Boulevard |
ZIP | 94080 |
Phone | 650 881 6500 |
Website | https://www.sutrobio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 292 |
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Q&A For Sutro Biopharma, Inc. Stock
What is a current S09.F stock price?
Sutro Biopharma, Inc. S09.F stock price today per share is 3.76 EUR.
How to purchase Sutro Biopharma, Inc. stock?
You can buy S09.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sutro Biopharma, Inc.?
The stock symbol or ticker of Sutro Biopharma, Inc. is S09.F.
Which industry does the Sutro Biopharma, Inc. company belong to?
The Sutro Biopharma, Inc. industry is Biotechnology.
How many shares does Sutro Biopharma, Inc. have in circulation?
The max supply of Sutro Biopharma, Inc. shares is 81.79M.
What is Sutro Biopharma, Inc. Price to Earnings Ratio (PE Ratio)?
Sutro Biopharma, Inc. PE Ratio is now.
What was Sutro Biopharma, Inc. earnings per share over the trailing 12 months (TTM)?
Sutro Biopharma, Inc. EPS is -1.73 EUR over the trailing 12 months.
Which sector does the Sutro Biopharma, Inc. company belong to?
The Sutro Biopharma, Inc. sector is Healthcare.